

The
Progressive
age of **quenching**



VONOQUENCH

Vonoprazan 10 mg and 20 mg Tablets


VONOQUENCH

Vonoprazan 10 mg and 20 mg Tablets

BACKGROUND:

- Over the time, GERD has become common globally. Despite PPI treatment, many patients remain dissatisfied. Notably, H.pylori infection inversely correlates with GERD. Global prevalence of GERD is 20% and H. pylori is 50%.^{1,2,3}
- Vonoprazan (VPZ), a novel potassium-competitive acid blocker (P-CAB), provides stronger, faster, and longer acid suppression than PPIs, showing superior efficacy against GERD, H. pylori, and ulcers, addressing therapy limitations.¹

MECHANISM OF ACTION OF PPIs AS COMPARED WITH P-CABS⁴:



- PPIs convert to their active form in acid milieu within the secretory canaliculi and bind covalently to H⁺ /K⁺-ATPases in a stimulated parietal cell.
- P-CABs accumulate in high concentrations in secretory canaliculi and bind reversibly to H⁺/K⁺-ATPases **without requiring an acidic environment for activation.**

VONOPRAZAN FULL & FAST EFFECT FROM FIRST DOSE⁵:




Fig. Time course of acid inhibition by P-CABs and PPIs.



CLINICAL RESEARCH

① EFFICACY OF VONOPRAZAN FOR PROTON PUMP INHIBITOR-RESISTANT REFLUX ESOPHAGITIS (RE)⁶

Total Patients: 24 PPI-resistant RE patients **Duration:** 4 Weeks **Dose:** Vonoprazan 20 mg
Result:




Fig. Endoscopic healing rate of vonoprazan therapy at 20 mg for 4 weeks for proton pump inhibitor-resistant reflux esophagitis. LA: Los Angeles.

Conclusion: Vonoprazan effectively treats most PPI-resistant RE patients. Among these patients, a 4-week, 20 mg VPZ course resulted in a 90% endoscopic healing rate.

② COMPARATIVE REVIEW OF FIRST-LINE H. PYLORI ERADICATION THERAPIES⁷

VPZ-Based Regimen		PPI-Based Regimen	
Regimen	Eradication Rate	Regimen	Eradication Rate
VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	95.8%	LPZ: 30 mg bid or RPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	69.6%
VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	90.9%	RPZ: 10 mg bid or ESO: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	72.8%

*AMX: Amoxicillin, CLR: Clarithromycin, ESO: Esomeprazole, LPZ: Lansoprazole, RPZ: Rabeprazole, VPZ: Vonoprazan.

VONOQUENCH

Vonoprazan 10 mg and 20 mg Tablets

DESCRIPTION:

Vonoquench-10/20 tablets contain Vonoprazan, a potent inhibitor of gastric acid secretion, available in 10 mg and 20 mg strengths. Vonoprazan (VPZ) offers superior symptomatic relief through its innovative mechanism and sustained therapeutic effectiveness.

INDICATION:

- Treatment of reflux esophagitis (RE), gastric ulcer (GU) & duodenal ulcer (DU).
- Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin / NSAIDs administration.
- In Helicobacter pylori treatment in combination with both amoxicillin and clarithromycin or with amoxicillin alone.

MECHANISM OF ACTION:

Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H⁺, K⁺-ATPase enzyme system in a potassium-competitive manner.

VONOQUENCH

It suppresses basal and stimulated gastric acid secretion at the secretory surface of gastric parietal cells.

KEY FEATURES:

- Faster Onset:** A faster onset of action than PPIs.⁸
- Non-Acid Activation:** Doesn't require stomach acid for effectiveness.⁸
- Meal independent:** Vonoprazan effect is not influenced by meals.⁴
- Stronger Suppression:** Provides potent and sustained inhibition of gastric acid secretion.¹
- Long Lasting Effect:** Stable and persists in the stomach, exerting a long-lasting effect.⁸
- Potassium Competitive:** Competes with potassium for proton pump binding, boosting efficacy.⁸
- Higher Efficacy:** Superior effectiveness in treating conditions like GERD and H. pylori infection compared to PPIs.^{1,9}
- Reduced Resistance:** Suitable alternative for patients with PPI resistance or intolerance.¹⁰

DOSAGE:

The recommended dose of vonoprazan is 10 mg-20 mg OD or as suggested by the healthcare professional.

PRESENTATION:

Vonoquench-10/20 is available as a strip of 10 tablets.

REFERENCES:

1. Kang et al. *Medicine* (2018) 97:39. | 2. *Ann Esophagus* 2022;5:7 | 3. *World J Gastroenterol* 2014 February 14; 20(6): 1503-1509 | 4. *Gastroenterology* Rev 2023; 18 (1): 47-55 | 5. *Gastroenterology*. 2018 Dec;14:570-90. | 6. *Digestion* 2017;95:156-161 | 7. *Pharmaceuticals* 2020, 13, 276 | 8. *Japanese Society of Gastroenterology* 2020, 31 August 2020. | 9. Murakami K, et al. *Gut* 2016;65:1439-1446. | 10. *BIOMEDICAL REPORTS* 14: 32, 2021



Scan for more
Prescribing Information

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: +91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2024 All rights reserved, La Renon Healthcare Private Limited